Based on our results we suggest that the combination of bortezomib with JNK or autophagy inhibitors could be exploited to improve the outcome of therapy of this aggressive B cell lymphoma. The gene discussed is MAPK8; the disease is B-cell non-Hodgkin lymphoma.